Allogene Therapeutics, Inc. (ALLO:NASDAQ) closed at $1.25 on October 23, 2026, unchanged on the day. The stock trades 72.0% below its 52-week high of $4.46 and 20.2% above its 52-week low of $1.04. Over the past year, it gained 4.2%. Allogene Therapeutics, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 23, 2025, ALLO closed higher on 108 days (43%). Its best day was February 17, 2026 (+20.00%) and its worst was April 14, 2026 (-25.49%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 2 times.
Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Find more stocks like ALLO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.